Dankar Razan, Habib Toni, Tfaily Mira, Makkouk Dina, Barakat Salim, Habib Bruno, Kaspar Chris, Khalil Ali
Department of Internal Medicine, Lebanese University, Faculty of Medical Sciences, Beirut, Lebanon.
Department of Internal Medicine, Staten Island University Hospital, Staten Island, New York, USA.
Asian J Endosc Surg. 2025 Jan-Dec;18(1):e70050. doi: 10.1111/ases.70050.
Current treatment options for obesity typically involve a combination of lifestyle changes, medications, and bariatric surgeries. This study aimed to assess the safety profile of the endoscopic sleeve gastroplasty (ESG), which is a novel non-invasive approach, as compared to laparoscopic sleeve gastrectomy (LSG) and to correlate their weight loss effectiveness and complication risk in Lebanese patients.
This is a retrospective study, including 70 patients who underwent ESG at Fouad Khoury Hospital and 70 patients who underwent LSG at Trad Hospital, between September 2021 and March 2023. Data collection targeted the patients' medical records and included their demographic characteristics (age, sex, weight, height, BMI), comorbidities, and post-procedural information. Weight and BMI (pre-op, 6-months post-op, and 1-year post-op) were collected. Total body weight loss was calculated, and analysis was performed using SPSS version 25.
Patients who underwent ESG were distributed between 43 (61.4%) females and 27 (38.6%) males, with an average age of 38.07 ± 10.78 years. Patients who underwent LSG were distributed between 42 (60%) females and 28 (40%) males, with an average age of 33.99 ± 10.55 years. Both ESG and LSG resulted in significant weight loss, but LSG achieved greater total body weight loss at 6 and 12 months. ESG was associated with significantly shorter hospital stays (9.14 h vs. 27.77 h, p < 0.001) and fewer adverse events (8.5% vs. 17.1%, p = 0.111). New-onset GERD was more frequent after LSG (20% vs. 4.3%, p = 0.004).
ESG offers a less invasive approach with a potentially more favorable short-term safety profile and faster recovery, while LSG yields greater total body weight loss. ESG may be a suitable alternative for patients with a higher BMI. Further research is needed to assess long-term outcomes and cost-effectiveness.
目前肥胖症的治疗方案通常包括生活方式改变、药物治疗和减肥手术的综合应用。本研究旨在评估内镜下袖状胃成形术（ESG）这一新型非侵入性方法与腹腔镜袖状胃切除术（LSG）相比的安全性，并关联它们在黎巴嫩患者中的减重效果和并发症风险。
这是一项回顾性研究，纳入了2021年9月至2023年3月期间在福阿德·库里医院接受ESG的70例患者以及在特拉德医院接受LSG的70例患者。数据收集针对患者的病历，包括他们的人口统计学特征（年龄、性别、体重、身高、BMI）、合并症和术后信息。收集了体重和BMI（术前、术后6个月和术后1年）。计算总体重减轻情况，并使用SPSS 25版进行分析。
接受ESG的患者中，女性43例（61.4%），男性27例（38.6%），平均年龄为38.07±10.78岁。接受LSG的患者中，女性42例（60%），男性28例（40%），平均年龄为33.99±10.55岁。ESG和LSG均导致显著减重，但LSG在6个月和12个月时实现了更大的总体重减轻。ESG与显著更短的住院时间相关（9.14小时对27.77小时，p<0.001）以及更少的不良事件（8.5%对17.1%，p=0.111）。LSG后新发胃食管反流病更常见（20%对4.3%，p=0.004）。
ESG提供了一种侵入性较小的方法，具有潜在更有利的短期安全性和更快的恢复速度，而LSG实现了更大的总体重减轻。ESG可能是BMI较高患者的合适替代方案。需要进一步研究来评估长期结果和成本效益。
